BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27

• Press Releases

  GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update

  February 26, 2026

   · 

  9 min read
• Press Releases

  OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer

  February 26, 2026

   · 

  3 min read
• Press Releases

  Flourish Research® Announces Strategic Partnership with Capitol Imaging Services and Upcoming Launch of Flourish Imaging™ in Gainesville, Georgia

  February 26, 2026

   · 

  2 min read
• Press Releases

  ARUP Creates Innovation Central Laboratory To Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

  February 26, 2026

   · 

  3 min read
• Press Releases

  GEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221, Investigational Next‑Generation Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)

  February 26, 2026

   · 

  5 min read
• Press Releases

  More Organ Donations Now Come from People Who Die After Their Heart Stops Beating

  February 26, 2026

   · 

  6 min read
• Press Releases

  Transformative Biotech Names Mark Kelleher, PhD as Executive VP of R&D

  February 26, 2026

   · 

  2 min read
• Press Releases

  Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

  February 26, 2026

   · 

  13 min read
• Press Releases

  FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

  February 26, 2026

   · 

  12 min read
• Press Releases

  Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

  February 26, 2026

   · 

  11 min read